The short version of placebo-controlled trial fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-06 and is reviewed periodically as new material appears.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic analogue of alpha-MSH |
| Molecular formula | C50H68N14O10 | Acetate salt form commonly reported |
| Molecular mass | ~1025 Da | Monoisotopic value near 1025.2 |
| Key structural motif | Lactam bridge | Asp side chain to Lys side chain |
| Solid appearance | White to off-white powder | Lyophilised and hygroscopic |
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Conversely, the change may allow the cell to continue functioning albeit differently, and the mutation can be passed on to the organism's offspring. If this change does not result in any significant physical disadvantage to the offspring, the possibility exists that this mutation will persist within the population. The possibility also exists that the change in function becomes advantageous. In either case, while being subjected to the processes of natural selection, the point mutation has been accepted into the genetic pool. The 20 amino acids translated by the genetic code vary greatly by the physical and chemical properties of their side chains. However, these amino acids can be categorised into groups with similar physicochemical properties. Substituting an amino acid with another from the same category is more likely to have a smaller impact on the structure and function of a protein than replacement with an amino acid from a different category. Consequently, acceptance of point mutations depends heavily on the amino acid being replaced in the mutation, and the replacement amino acid. The PAM matrices are a mathematical tool that account for these varying rates of acceptance when evaluating the similarity of proteins during alignment.
Émilie du Châtelet (1706–1749) proposed and tested the hypothesis of the conservation of total energy, as distinct from momentum. Inspired by the theories of Gottfried Leibniz, she repeated and publicized an experiment originally devised by Willem 's Gravesande in 1722 in which balls were dropped from different heights into a sheet of soft clay. Each ball's kinetic energy—as indicated by the quantity of material displaced—was shown to be proportional to the square of the velocity. The deformation of the clay was found to be directly proportional to the height from which the balls were dropped, equal to the initial potential energy. Some earlier workers, including Newton and Voltaire, had believed that "energy" was not distinct from momentum and therefore proportional to velocity. According to this understanding, the deformation of the clay should have been proportional to the square root of the height from which the balls were dropped. In classical physics, the correct formula is
Some neurotransmitters are secreted and released in a manner similar to peptide hormones, and certain "neuropeptides" function as both neurotransmitters in the nervous system and hormones in the bloodstream. When a peptide hormone binds to its receptor on the cell surface, it activates a second messenger within the cytoplasm, triggering signal transduction pathways that lead to specific cellular responses. Certain peptides, such as angiotensin II, basic fibroblast growth factor-2, and parathyroid hormone-related protein, can also interact with intracellular receptors in the cytoplasm or nucleus through an intracrine mechanism.
=== Warning signs === Before the development of noma, there may be simple gingivitis: Inflammation and reddening of the gums, which bleed when touched or during toothbrushing. The WHO recommends disinfectant mouthwash; if not available, use warm, salted water that has been boiled. A high-protein diet, Vitamin A supplements, and patient education on oral hygiene are also recommended to prevent noma from progressing to the acute stages.
=== Oxygen and atmosphere control === Oxygen scavengers, also called oxygen absorbers, remove residual oxygen from a sealed package. Reducing oxygen can slow lipid oxidation, colour changes, vitamin degradation, mould growth, and the growth of aerobic spoilage organisms. Iron-based oxygen absorbers commonly contain iron powder and supporting ingredients that allow oxidation to occur. Other systems use ascorbic acid, enzymes, unsaturated organic compounds, microorganisms, antioxidants, or oxygen-scavenging polymers. The active material may be supplied in a sachet, card, label, bottle closure, tray, film, liner, or moulded package component. Sachets must be clearly identified and protected against accidental opening or ingestion. In practical dry-food storage, oxygen-absorber sachets may be placed inside suitable high-barrier Mylar pouches before heat sealing. The food type, moisture level, absorber capacity, seal integrity, and package barrier must be appropriate for reduced-oxygen storage. The effectiveness of an oxygen scavenger is partly determined by the package's oxygen transmission rate. A low-transmission barrier limits the amount of oxygen entering after the initial oxygen has been removed. A high-barrier film remains passive packaging when used without an active component. Modified atmosphere packaging changes the concentration of gases surrounding a product. Nitrogen, carbon dioxide, oxygen, or mixtures of these gases may be selected according to the product and its spoilage mechanisms.
Sources: en.wikipedia.org
Huang for a method to produce graphene-based on exfoliation followed by attrition. In 2014, inventor Larry Fullerton patented a process for producing single-layer graphene sheets by graphene's strong diamagnetic properties.
APP operates the technical operation while Eastern Carolina Pathology, P.A., the affiliated four-pathologist medical practice, stays independent and continues to be owned and managed by the pathologists. On January 17, 2011, the firm completed the acquisition of the technical operation of Palm Beach Pathology, P.A. in West Palm Beach, Florida. APP operates the technical operation while Palm Beach Pathology, P.A., the affiliated six-pathologist medical practice, stays independent and continues to be owned and managed by the pathologists. In 2020, the company was listed in Global Clinical Reference Laboratory Services report as a Top Player on the market.
Phthalimide is used as a precursor to anthranilic acid, a precursor to azo dyes and saccharin. Alkyl phthalimides are useful precursors to amines in chemical synthesis, especially in peptide synthesis where they are used "to block both hydrogens and avoid racemization of the substrates". Alkyl halides can be converted to the N-alkylphthalimide:
== Veterinary use == Pethidine provides analgesia for 60 to 90 minutes in the cat and dog. Pethidine is less effective in horses, with IV, SC, and IM administration failing to provide thermal antinociception. Epidural administration of pethidine into the caudal area provided 4-5 hours of analgesia with no cardiovascular depression and only minor sedation. Due to the short duration of analgesia and side effects pethidine is not commonly used with other opioids being used instead. Pethidine is vagolytic but high doses cause bradycardia due to cardiac depression. Pethidine is metabolised by the hepatic enzyme CYP450 via N-demethylation to produce normeperidine. Normeperidine is excitotoxic and can cause myoclonus when too much pethidine is administered. The treatment for these side effects are benzodiazepines. Histamine release following IV administration can cause flare reaction, pruritus, hypersalivation, urination, defaecation, and tachypnoea. IM injection can cause localised oedema and erythema.
== Formation of sugar-carbamino == The sugar-carbamino is formed through a C-glycosidic linkage with the amino acid side chain via various linkers. The synthesis involves introducing annulation to appropriate amino acid residues to rigidify glycopeptides, followed by Diels-Alder cycloadditions to fuse cyclic α- and β-amino acids to the sugar moiety. This also involves the preparation of fused bicyclic C-glycosyl α-amino acid 4, which is confirmed through 2D NMR experiments, particularly NOESY. The approach to conformationally constrained (annulated)-C-glycosyl α- and β-amino acids is based upon the Diels-Alder reaction of pyranose dienes with α- and β-nitro acrylic esters.
Sources: en.wikipedia.org
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.
The two compounds share the same cyclic core and are both non-selective melanocortin agonists. They differ chiefly at the C-terminus, where bremelanotide carries a free carboxylic acid and melanotan II a terminal amide.
Receptor binding profiles are well characterised in vitro, but the downstream pathway linking MC4R activation to behavioural effects is not fully mapped. Several intermediate neural circuits have been proposed without definitive confirmation.
It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.